SCHEMBL4237299

SCHEMBL4237299

O=C(NCC1C2CCC1CN(Cc1ccccc1)C2)c1ccccc1-c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.54
CHRNA4 P43681 2/20 0.54
CHRNB4 P30926 1/20 0.52
CHRNA3 P32297 1/20 0.52
CCR3 P51677 4/20 0.45
KMT2A Q03164 2/20 0.45
HTT P42858 1/20 0.45
CHRM2 P08172 1/20 0.44
CHRM4 P08173 1/20 0.44
CHRM1 P11229 1/20 0.44
CHRM3 P20309 1/20 0.44
GAA P10253 1/20 0.44
HCRTR1 O43613 2/20 0.43
HCRTR2 O43614 2/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
PDCD1 Q15116 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4240402 0.90 DRD2 (0.51) CHRNB2CHRNA4CHRM4GAA
SCHEMBL4242462 0.84 DRD2 (0.43)
SCHEMBL4245976 0.84 DRD2 (0.58) CHRM4
SCHEMBL4189224 0.81 GRIN2B (0.48) KMT2A
SCHEMBL4246862 0.81 ALDH1A1 (0.50) CCR3KMT2AHTTGAAMEN1
SCHEMBL4237622 0.81 CHRNB2 (0.52) CHRNB2CHRNA4CHRNB4CHRNA3KMT2A
SCHEMBL4248205 0.78 BACE1 (0.55) KMT2AMEN1ALDH1A1LMNA
SCHEMBL4240897 0.78 MEN1 (0.54) CHRNB2CHRNA4CHRNB4CHRNA3KMT2A
SCHEMBL4246929 0.76 MCHR2 (0.55) CHRM4
SCHEMBL4200481 0.75 GRIN2B (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012116-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2009-01-08 US claimed
US-20090012116-A1 Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2009-01-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012116-A1 Muscarinic Receptor Antagonists CHRM3, CHRM2, CHRM5 CHRNB2 26/4885CHRNA4 31/4885CHRNB4 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.